Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...
RFK Jr. says he’ll keep making money on anti-vaccine lawsuits while in office
The secretary of Health and Human Services nominee wrote in an ethics agreement that he would keep receiving contingency fees ...
health.wusf.usf.edu14d
RFK Jr. plans to keep a financial stake in lawsuits against the drugmaker Merck
a law firm suing Merck over claims that the pharmaceutical company failed to properly warn consumers about risks from its HPV ...
Seeking Alpha6d
MRK Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...
Yahoo Finance23d
Merck is broadening its pipeline as Keytruda’s patent cliff looms
To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Merck & Co.’s Keytruda is the world’s best-selling drug and has been a cancer juggernaut for more than a ...
pharmaphorum7d
Merck gets FDA nod for new antibiotic, but says use with care
Ed Cox, director for the Office of Antimicrobial Products at the ... of imipenem against certain imipenem-resistant strains, and Merck says the cUTIs that are treatable with Recarbrio include ...
Business Insider22d
Merck & Company: Strategic Shifts and Upcoming Catalysts Amidst Keytruda Challenges
Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target to $119.00. Discover outperforming stocks and invest ...